The IL27 knockout PaTu 8988t polyclonal cells are a CRISPR/Cas9-edited human pancreatic cancer cell population designed for loss-of-function studies of the IL27 gene. Derived from the PaTu 8988t cell line, this polyclonal pool provides a genetically heterogeneous model that captures the variability of CRISPR-mediated gene disruption across the population, enabling robust functional analysis without clonal bias. It allows interrogation of IL27 in tumor cell biology and immune modulation within a well-characterized metastatic pancreatic cancer context, supporting scalable experiments for pathway dissection, drug response profiling, and immune cell co-culture assays.
The PaTu 8988t host cell line was established from a liver metastasis of human pancreatic ductal adenocarcinoma (PDAC) and harbors an activating KRAS mutation. This model is widely employed to study metastatic progression, tumor microenvironment interactions, and therapeutic resistance. The KRAS-mutant background provides a clinically relevant context for investigating oncogenic signaling crosstalk with cytokine networks such as IL27.
IL27 is a heterodimeric cytokine composed of EBI3 and p28 that signals through IL27RA/gp130 receptor complexes. Ligand binding activates JAK1, JAK2, and TYK2, leading to phosphorylation of STAT1 and STAT3. These transcription factors induce T-bet and IL-10 expression while upregulating SOCS1 and SOCS3. Upstream activators include TLR agonists, IFN??, CD40L, and the NF-??B/IRF1 axis. IL27 promotes Th1 differentiation and anti-inflammatory responses, positioning it as a key modulator of anti-tumor immunity.
In the PDAC microenvironment, IL27 signaling can influence tumor immune evasion through autocrine or paracrine mechanisms that alter immunomodulatory molecule expression and T cell-mediated cytotoxicity. By disrupting IL27 in this KRAS-mutant metastatic model, researchers can dissect how tumor-derived cytokines impact immune surveillance and tumor progression, particularly the interplay between oncogenic KRAS signaling and STAT1/STAT3 activation. This knockout tool also allows evaluation of whether IL27 loss sensitizes pancreatic cancer cells to immunotherapies or targeted agents.
The IL27 knockout PaTu 8988t polyclonal cells are amenable to a suite of experimental approaches, including RT-qPCR and western blotting for gene and protein confirmation, ELISA for secreted factors like IL-10, flow cytometry for immune phenotype characterization, and T cell co-culture systems for functional immune readouts. Transcriptomic analysis via RNA-seq and phospho-STAT profiling further elucidate downstream signaling alterations. These applications support drug target validation and mechanistic studies of IL27 in pancreatic cancer and other solid tumors. For further information or to discuss how this knockout model can accelerate your research, please contact Ascent Research.
